MedTrace Logo

Prospective Observational Epidemiologic Study of Maraviroc's Safety

NCT00665561 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2022-10-18

Study results available
· View outcomes & findings →

Summary

The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Maraviroc along with an optimized background antiretroviral drug regimen

Maraviroc prescribed per approved local label.

DRUG

Optimized background antiretroviral drug regimen without maraviroc

Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2019-02-14
Completion
2019-02-14
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Brazil
  • Canada
  • France
  • Germany
  • Greece
  • Italy
  • Puerto Rico
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00665561 on ClinicalTrials.gov